Nanoscale Advances,
Journal Year:
2024,
Volume and Issue:
6(17), P. 4417 - 4425
Published: Jan. 1, 2024
The
combination
of
photoswitchability
and
bioactivity
in
one
compound
provides
interesting
opportunities
for
photopharmacology.
Here,
we
report
a
hybrid
that
addition
allows
its
visual
localization.
It
is
the
first
demonstration
kind
it
even
shows
high
photoswitchability.
multifunctional
nanomaterial
hybrid,
which
present,
composed
luminescent
LaVO
Angewandte Chemie International Edition,
Journal Year:
2023,
Volume and Issue:
62(30)
Published: April 7, 2023
Photopharmacology
is
an
attractive
approach
for
achieving
targeted
drug
action
with
the
use
of
light.
In
photopharmacology,
molecular
photoswitches
are
introduced
into
structure
biologically
active
small
molecules
to
allow
optical
control
their
potency.
Going
beyond
trial
and
error,
photopharmacology
has
progressively
applied
rational
design
methodologies
devise
light-controlled
bioactive
ligands.
this
review,
we
categorize
photopharmacological
efforts
from
standpoint
medicinal
chemistry
strategies,
focusing
on
diffusible
photochromic
ligands
modified
that
operate
through
E-Z
bond
isomerization.
vast
majority
cases,
photoswitchable
designed
as
analogs
existing
compounds,
a
variety
approaches.
By
analyzing
in
detail
comprehensive
list
instructive
examples,
describe
state
art
discuss
future
opportunities
photopharmacology.
Journal of the American Chemical Society,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 13, 2025
Molecular
photoswitch
research
has
drawn
much
attention
in
the
last
century
owing
to
its
great
potential
development
of
smart
materials.
However,
photoswitches
suitable
for
constructing
light-responsive
luminescent
materials
remain
limited,
especially
those
involving
triplet-state
phosphorescence.
Herein,
we
designed
a
novel
molecular
based
on
conformation
transition
phenothiazine
derivatives,
minimizing
steric
hindrance
(-CH
Journal of the American Chemical Society,
Journal Year:
2024,
Volume and Issue:
146(3), P. 2062 - 2071
Published: Jan. 16, 2024
A
family
of
neurodegenerative
diseases,
including
Huntington's
disease
(HD)
and
spinocerebellar
ataxias,
are
associated
with
an
abnormal
polyglutamine
(polyQ)
expansion
in
mutant
proteins
that
become
prone
to
form
amyloid-like
aggregates.
Prior
studies
have
suggested
a
key
role
for
β-hairpin
formation
as
driver
nucleation
aggregation,
but
direct
experimental
been
challenging.
Toward
such
research,
we
set
out
enable
spatiotemporal
control
over
by
the
introduction
photosensitive
β-turn
mimic
polypeptide
backbone,
consisting
newly
designed
azobenzene
derivative.
The
reported
derivative
overcomes
limitations
prior
approaches
poor
photochemical
properties
imperfect
structural
compatibility
desired
structure.
new
azobenzene-based
was
designed,
synthesized,
found
display
improved
properties,
both
after
incorporation
into
backbone
polyQ
polypeptide.
two
isomers
azobenzene-polyQ
peptide
showed
different
aggregate
structures
fibrils,
demonstrated
electron
microscopy
solid-state
NMR
(ssNMR).
Notably,
only
peptides
which
structure
stabilized
(azobenzene
cis
configuration)
closely
reproduced
spectral
fingerprints
toxic,
β-hairpin-containing
fibrils
formed
huntingtin
protein
fragments
implicated
HD.
These
findings
will
better
deciphering
roles
aggregation
processes
HD
other
amyloid-related
diseases.
Chemistry - A European Journal,
Journal Year:
2024,
Volume and Issue:
30(15)
Published: Jan. 13, 2024
Abstract
In
addition
to
the
discovery
of
new
(modified)
potent
antibiotics
combat
antibiotic
resistance,
there
is
a
critical
need
develop
novel
strategies
that
would
restrict
their
off‐target
effects
and
unnecessary
exposure
bacteria
in
our
body
environment.
We
report
set
photoswitchable
arylazopyrazole‐modified
norfloxacin
present
high
degree
bidirectional
photoisomerization,
impressive
fatigue
resistance
reasonably
cis
half‐lives.
The
irradiated
isomers
most
compounds
were
found
exhibit
nearly
equal
or
higher
antibacterial
activity
than
against
Gram‐positive
bacteria.
Notably,
norfloxacin‐resistant
S.
aureus
bacteria,
visible‐light‐responsive
p
‐SMe‐substituted
derivative
showed
remarkably
antimicrobial
potency
(MIC
0.25
μg/mL)
state,
while
was
reduced
by
24‐fold
case
its
non‐irradiated
state.
estimated
be
retained
for
more
7
hours.
This
first
demonstrate
direct
photochemical
control
growth
antibiotic‐resistant
show
highest
difference
between
states
antibiotic.
Additionally,
both
non‐harmful
human
cells.
Molecular
modellings
performed
identify
underlying
reason
behind
high‐affinity
binding
isomer
topoisomerase
IV
enzyme.
Angewandte Chemie International Edition,
Journal Year:
2021,
Volume and Issue:
60(37), P. 20178 - 20183
Published: June 3, 2021
Covalent
kinase
inhibitors
account
for
some
of
the
most
successful
drugs
that
have
recently
entered
clinic
and
many
others
are
in
preclinical
development.
A
common
strategy
is
to
target
cysteines
vicinity
ATP
binding
site
using
an
acrylamide
electrophile.
To
increase
tissue
selectivity
inhibitors,
it
could
be
advantageous
control
reactivity
these
electrophiles
with
light.
Here,
we
introduce
covalent
JNK3
function
as
photoswitchable
affinity
labels
(PALs).
Our
lead
compounds
contain
a
diazocine
photoswitch,
poor
non-covalent
dark,
become
effective
after
irradiation
visible
proposed
mode
action
supported
by
X-ray
structures
explain
why
unreactive
dark
undergo
proximity-based
attachment
following
exposure
Current Opinion in Pharmacology,
Journal Year:
2022,
Volume and Issue:
63, P. 102192 - 102192
Published: March 4, 2022
The
field
of
photopharmacology
Class
A
GPCR
ligands
has
recently
attracted
attention.
In
this
review
we
analyze
31
papers
on
currently
available
photoswitchable
for
GPCRs.
Using
the
six
most
recurring
terms
all
combined
paper
abstracts,
one
can
extract
overarching
goal
area
research:
"Photoswitchable
control
receptor
activity
with
light"
(represented
in
TOC
graphic).
We
design,
photochemistry
and
pharmacology
ligands.
Trends,
challenges
limitations
will
be
discussed.
number
efficient
that
allow
optical
modulation
function
various
vitro
assays
are
presented.
Moreover,
vivo
is
within
reach
first
reports
to
end
highlighted.
Nature Communications,
Journal Year:
2022,
Volume and Issue:
13(1)
Published: June 9, 2022
Abstract
In
the
central
nervous
system
(CNS),
excitatory
amino
acid
transporters
(EAATs)
mediate
uptake
of
neurotransmitter
glutamate
and
maintain
its
low
concentrations
in
synaptic
cleft
for
avoiding
neuronal
cytotoxicity.
Dysfunction
EAATs
can
lead
to
many
psychiatric
diseases.
Here
we
report
cryo-EM
structures
human
EAAT2
an
inward-facing
conformation,
presence
substrate
or
selective
inhibitor
WAY-213613.
The
is
coordinated
by
extensive
hydrogen
bonds
further
stabilized
HP2.
WAY-213613
occupies
a
similar
binding
pocket
that
glutamate.
Upon
association
with
WAY-213613,
HP2
undergoes
substantial
conformational
change,
turn
stabilizes
forming
hydrophobic
interactions.
Electrophysiological
experiments
elucidate
unique
S441
plays
pivotal
roles
hEAAT2
I464-L467-V468
cluster
acts
as
key
structural
determinant
inhibition
this
transporter
Journal of Nanotheranostics,
Journal Year:
2023,
Volume and Issue:
4(1), P. 55 - 85
Published: Feb. 8, 2023
Currently,
intelligent,
responsive
biomaterials
have
been
widely
explored,
considering
the
fact
that
provide
controlled
and
predictable
results
in
various
biomedical
systems.
Responsive
nanostructures
undergo
reversible
or
irreversible
changes
presence
of
a
stimulus,
stimuli
can
be
temperature,
magnetic
field,
ultrasound,
pH,
humidity,
pressure,
light,
electric
etc.
Different
types
being
used
drug
delivery
shall
explained
here.
Recent
research
progress
design,
development
applications
comprising
is
also
described
More
emphasis
will
given
on
explored
for
smart
at
target
site
such
as
wound
healing,
cancer
therapy,
inflammation,
pain
management
order
to
achieve
improved
efficacy
sustainability
with
lowest
side
effects.
However,
it
still
big
challenge
develop
well-defined
ordered
output;
thus,
challenges
faced
during
design
these
included
this
article.
Clinical
perspectives
applicability
targeted
discussed
Angewandte Chemie,
Journal Year:
2023,
Volume and Issue:
135(30)
Published: April 7, 2023
Abstract
Photopharmacology
is
an
attractive
approach
for
achieving
targeted
drug
action
with
the
use
of
light.
In
photopharmacology,
molecular
photoswitches
are
introduced
into
structure
biologically
active
small
molecules
to
allow
optical
control
their
potency.
Going
beyond
trial
and
error,
photopharmacology
has
progressively
applied
rational
design
methodologies
devise
light‐controlled
bioactive
ligands.
this
review,
we
categorize
photopharmacological
efforts
from
standpoint
medicinal
chemistry
strategies,
focusing
on
diffusible
photochromic
ligands
modified
that
operate
through
E‐Z
bond
isomerization.
vast
majority
cases,
photoswitchable
designed
as
analogs
existing
compounds,
a
variety
approaches.
By
analyzing
in
detail
comprehensive
list
instructive
examples,
describe
state
art
discuss
future
opportunities
photopharmacology.